142 Sansome St
Tel: (949) 9999999
3 articles with 89bio
89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH- Study
89bio, Inc. today announced that it has completed target enrollment of 20 patients in the paired-biopsy, open-label histology cohort in biopsy-confirmed fibrosis stage F2 – F3 NASH patients.
89bio, Inc. today announced that Company’s Management will participate in the following upcoming investor conferences in June: SVB Leerink CybeRx Series: Liver Disease Day Format: One-on-one investor meetings Date: Thursday, June 17, 2021
89bio, Inc. today announced the initiation of ENLIVEN, a Phase 2b trial evaluating BIO89-100 for the treatment of patients with fibrosis stage 2 or 3 non-alcoholic steatohepatitis (NASH).